摘要
目的:评价唑来膦酸与阿仑膦酸钠治疗Ⅰ型骨质疏松症的疗效和安全性。方法:选取本院100例Ⅰ型骨质疏松症患者,分成A、B组,A组静脉滴注唑来膦酸注射液5mg,每年1次,共2次;B组口服阿仑膦酸钠70mg,每周1次。2组均补充碳酸钙D3600mg·d-1,治疗时间均为18个月。测定治疗前、后腰椎及髋部骨密度(BMD)值和血钙(Ca2+)、碱性磷酸酶(ALP)等生化指标,利用Oswestry功能障碍指数(ODI指数)评价治疗前、后疼痛和功能改善情况等。结果:2组治疗前、后生化指标,除治疗12、18个月后ALP变化差异有统计学意义(P<0.05)外,其余差异均无统计学意义(P>0.05);2组治疗前、后ODI评分差异均有统计学意义(P<0.05),且治疗12、18个月后2组间比较差异均有统计学意义(P<0.05);2组治疗18个月后腰椎、髋部BMD值都有明显上升,与治疗前比较差异有统计学意义(P<0.05),治疗18个月后腰椎BMD值组间比较差异有统计学意义(P<0.05),但髋部BMD值组间比较差异无统计学意义(P>0.05)。结论:唑来膦酸与阿仑膦酸钠均能使Ⅰ型骨质疏松症患者显著改善功能并减轻疼痛,增加腰椎、髋部BMD值,长期使用均不影响肝、肾功能,且唑来膦酸比阿仑膦酸钠为更理想的选择。
OBJECTIVE： To evaluate the therapeutic efficacy and safety of zoledronic acid and alendronate sodium for type Ⅰ osteoporosis. METHODS： 100 patients with type Ⅰ osteoporosis were divided into group A and group B. Patients in group A were administered Zoledronic acid injection 5 mg once a year with intravenous infusion for two times; patients in group B took Alendro- hate sodium 70 mg once a week orally. Meanwhile, both groups were given Caltrate D3 600 mg·d-1 as supplement for 18 months. Biochemical indicators, including bone mineral density （BMD）, Ca2＋ and ALP in lumbar vertebra and coxa, were measured to eval- uate the pain and function improvement by Oswestry disability index （ODI）. RESULTS： Biochemical indicators of both groups had no significant difference before and after treatment （P〉0.05）, except that the difference of ALP had statistical significance after 12 months and 18 months of treatment （P〈0.05）. ODI score of both groups had statistical significance before and after treatment （P〈 0.05）, and there was statistical significance between 2 groups after 12 months and 18 months of treatment （P〈0.05） ; the BMD of lumbar vertebra and coxa in 2 groups increased significantly after 18 months of treatment, there was statistical difference with be- fore treatment （P〈0.05）, and the BMD of lumbar vertebra had significant difference between 2 groups （P〈0.05）. The BMD of coxa had no significant difference between 2 groups （P〉0.05）. CONCLUSION： Both zoledronic acid and alendronate sodium can improve type Ⅰ osteoporosis patient＇ s function obviously, relive pain and raise BMD of lumbar vertebra and coxa. The long-term use of them does not affect liver and renal function, and zoledronic acid is better than alendronate sodium for type Ⅰ osteoporosis.
出处
《中国药房》
CAS
CSCD
2012年第42期3995-3997,共3页
China Pharmacy
关键词
唑来膦酸
阿仑膦酸钠
Ⅰ型骨质疏松症
疗效
Zoledronic acid
Alendronate sodium
Type Ⅰ osteoporosis
Therapeutic efficacy
